Feature | December 21, 2010



December 21, 2010 - The outcome of a recent expert consensus workshop offers six specific research recommendations in high-priority areas for sudden cardiac death (SCD) prediction and prevention. In the United States, SCD claims more than 250,000 lives annually and is the cause of half of all heart disease deaths. The report, “Sudden Cardiac Death (SCD) Prediction and Prevention: Report from a National Heart, Lung and Blood Institute (NHLBI) and Heart Rhythm Society Workshop,” was published in the November 30th issue of Circulation, an official journal of the American Heart Association.


The purpose of the workshop was to discover emerging approaches for improved prediction and prevention of SCD. The expert panel, which consisted of 24 arrhythmia investigators, was asked to consider the three broad areas of basic, clinical and population sciences.


“With the support of HRS and NHLBI, the workshop provided a unique venue to tackle complex biomedical issues,” said Glenn Fishman, M.D., FHRS, at New York University. “It afforded experts the opportunity to challenge old concepts and debate new ideas, with the hope that our individual and collective creativity would provide a useful roadmap for future exploration.”


The report outlines the outcomes of the expert consensus workshop – identifying knowledge gaps and a series of six specific recommendations for future research approaches in order to improve the prediction and prevention of SCD. Recommendations (not prioritized):


• Establish multi-scale integrative models, utilizing molecular, cellular, organ-level, animal and computational approaches, and apply these models to determine arrhythmia mechanisms.

• Establish high throughput experimental strategies to rapidly determine the functional relevance of newly discovered genes associated with arrhythmias in humans.

• Develop novel risk stratification strategies to improve outcomes in select populations, including those with ICD indications.

• Facilitate study of well-phenotyped SCD and control populations, including understudied subgroups.

• Develop and validate a SCD risk score utilizing phenotypic, biologic and non-invasive markers.

• Establish strategies for SCD prevention that can be employed in the general population, targeting intermediate risk phenotypes.


“This report is critical to helping us identify limitations of current understanding and point the way to the most fruitful research avenues for the future,” said Douglas Packer, president of the Heart Rhythm Society, M.D., FHRS. “The Society is pleased to collaborate with the NHLBI and we will continue our efforts toward innovation in electrophysiology and the prevention of sudden death for years to come.”


For more information: www.hrsonline.org


Related Content

MSCs, stem cells, end-stageheart failure, retrograde, coronary sinus,
News | Stem Cell Therapies| July 29, 2015
A new clinical trial to test how a high dose of stem cells delivered via a method called retrograde coronary sinus...
Itrevia 7 HF-T QP, Biotronik, CRT-D, first U.S. implantations, CLS algorithm
Feature | Cardiac Resynchronization Therapy Devices (CRT)| July 28, 2015
Biotronik announced the first patients have been successfully implanted with Itrevia HF-T QP cardiac resynchronization...
heart failure, Adaptive CRT trial, AdaptivCRT algorithm, readmissions
News | Heart Failure| July 22, 2015
Heart failure patients had a significantly lower chance of being readmitted within 30 days of discharge when treated...
HeartMate PHP, Thoratec, St. Jude medical

The HeartMate PHP (percutaneous heart pump) is the latest acute hemodynamic support technology released by Thoratec, which recently received CE mark in Europe. The PHP is currently in U.S.clinical trials.

Feature | Ventricular Assist Devices (VAD)| July 22, 2015
St. Jude Medical and Thoratec announced that the boards of directors of both companies have unanimously approved a...
Feature | Atrial Fibrillation| July 20, 2015
A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with...
NeoStem, PreSERVE study, AMI, ACC.15, NBS10, CD34 stem cells
Feature | Heart Failure| July 17, 2015
NeoStem Inc. presented updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study...
Medtronic, Reveal Linq ICM, in-office insertion, RIO 2 study
News | Implantable Cardiac Monitor (ICM)| July 16, 2015
Medtronic plc announced the first in-office implant of its miniaturized cardiac monitor as part of the Medtronic Reveal...
Feature | Business| July 08, 2015
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of...
Biosense Webster, Confidense Module, Carto, multi-electrode mapping, 3-D

Carto 3 System image courtesy of Biosense Webster

Technology | July 07, 2015
Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the...
Overlay Init